Background: Hepatitis B virus (HBV) is a major cause of chronic liver diseases worldwide, particularly cirrhosis and hepatocellular carcinoma, and the most important liver disease in Taiwan. However, little is known the impact of hepatitis b on osteoporotic patients. Objectives: This study aimed to determine if hepatitis b can increase the risk of mortality in patients with osteoporotic vertebral fracture. Methods: This retrospective study reviewed of cases of osteoporosis patients with acute vertebral fractures between 2001 and 2008. All associated co-morbidities were recorded. Kaplan-Meier and cox regression analysis were performed. Results: There were 432 patients with acute vertebral fractures. The mean age of 72.85±9.28. 31 (7.2%) patients had chronic hepatitis b. Using the Kaplan-Meier curve, hepatitis b had a significant effect on mortality (p<0.001, by log rank text). After adjusting for potential confounders, patients with hepatitis b still had a high mortality rate (p=0.019; HR: 2.436∼5.136) 2.137, 95% CI: 1.156∼5.136). The mortality rate also increased among smokers (p=0.026; HR: 3.6043.891; 95% CI: 1.056∼12.301).
from baseline values or absence of temperature normalization) could be up-dosed to 160 mg for an additional 12 weeks. The primary endpoint was safety and secondary endpoints included early signs of efficacy Results: 23 pts were included (10 and 13 in group 1 and group 2, respectively). 6 pts of group 1 were up-dosed to 160 mg. Baseline characteristics and safety and efficacy results are described in Table 1 . Most adverse events (AEs) (47) were considered as mild or moderate. Three serious AEs (SAE) were reported including two that were considered not related to the study drug and one possibly related according to the investigator (toxic optic neuropathy). Four premature discontinuations were related to AEs, including 3 cases of injection site reactions and 1 SAE. Systemic response as defined by ≥70% decrease of serum C-reactive protein (CRP) or normalization of CRP and ferritin levels was obtained in 2/10 and 6/13 pts of groups 1 and 2, respectively in the ITT analysis, and in 2/9 and 6/9 pts of groups 1 and 2, respectively, in the PP analysis. and swollen joint count)** 3/9 4/10 Skin rash resolution** 6/7 2/5 CRP level reduction by ≥70%** 2/10 6/13 Normalization of ferritin levels** 0/7 1/5 *Number of Pts, **Denominator corresponds to Pts with clinical manifestations or abnormal values at baseline.
